antibody molecule black background

Pharmacokinetics

<a href="https://www.bioagilytix.com/blog/category/lc-ms/">LC/MS</a>

Large Molecule Bioanalysis using LC/MS

  • December 21, 2023

Introduction to Large Molecules Therapeutics are an ever-evolving landscape of modalities which range in complexity but can be grouped into two broad categories: small molecules…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/biosimilars/">Biosimilars</a>

The State Of The Biosimilars Market

  • December 13, 2022

3 key challenges facing the biosimilars space in 2023 In 2010, the biopharma industry saw an abrupt patent cliff: a significant number of top-selling drugs…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/drug-development/">Drug Development</a>

What Parameters Are Acquired from a PK Study?

  • June 23, 2022

The term “Pharmacokinetics” is derived from “pharmakon” and “kinetikos” in ancient Greek, meaning “drug” and “position in motion,” respectively. It is one of the principal…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/pharmacokinetics/">Pharmacokinetics</a>

The Difference Between Pharmacokinetics and Pharmacodynamics

  • October 5, 2020

In the United States, the safety and efficacy of prescription and over-the-counter drugs are a top priority for our government, medical professionals, and pharmaceutical companies.…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

Bioanalytical Strategies to Support Biosimilar Programs: How BioAgilytix is Helping to Shape Best Practices

  • January 2, 2020

BioAgilytix has been fortunate enough to have several of our team members participate as co-authors on all three AAPS white papers in the series on…

Find Out More